Boston Scientific Corporation
BSXNew York Stock ExchangeFull coverage
Latest dossier
AI-generated
General research and analysis by Moatsight, not personalized investment advice. We show, you decide. Disclaimers
Q3 of fiscal year 2026 · Published Nov 1, 2026,
Boston Scientific sells single-use medical devices, from heart catheters and implants to scopes and stents, mostly to hospitals. Its two growth engines have turned: electrophysiology sales fell 5.3% and Watchman 5.9% organically in the third quarter of 2026, as rival pulsed field ablation catheters took US share and doctors referred fewer patients for left atrial appendage closure. An eight-day cyber outage in August cut about 3 points from third-quarter growth, which came in at 1.5%, but both franchises were slowing before it, and management calls 2027 the trough. Moatsight estimates revenue of about $21.1 billion over the next four quarters, roughly flat, with a recovery resting on product launches now expected in 2028.
What you pay
| Figure | At the close | 5-yr median | 5-yr range |
|---|---|---|---|
| P/E | No value: no close yet | No value: no price history | |
| EV/Sales | No value: no close yet | No value: no price history | |
| EV/EBITDA | No value: no close yet | No value: no price history | |
| Price/FCF | No value: no close yet | No value: no price history | |
| Market cap | No value: no close yet | ||
| Net debt and other claims(enterprise value minus market cap) | No value: no close yet | ||
| Enterprise value | No value: no close yet |
How the business is doing
| Figure | Last 12 months | 1-year change1-year | Yearly, 3 years | 8 quarters |
|---|---|---|---|---|
| Revenue | $21.1B | +8.9%(better for the company) | +15.3% | Each quarter is listed in the row's details. |
| Diluted EPS | $2.41 | No value: cannot be derived | No value: cannot be derived | Each quarter is listed in the row's details. |
| Free cash flow | $3.3B | −12.9%(worse for the company) | +25.2% | Each quarter is listed in the row's details. |
| Gross margin | 69.1% | +0.6 pp(better for the company) | −0.1 pp | Each quarter is listed in the row's details. |
| Operating margin | 18.7% | +0.8 pp(better for the company) | +1.0 pp | Each quarter is listed in the row's details. |
| Net margin | 16.6% | No value: cannot be derived | No value: cannot be derived | Each quarter is listed in the row's details. |
| Share count | 1.452B | −2.9%(better for the company) | −0.5% | Each quarter is listed in the row's details. |
How to read these figures
- Last 12 months: the latest four reported quarters added up, or a figure computed from them. The share count is its latest quarter's average.
- 1-year change: the last 12 months against the 12 months a year earlier. A margin's change is in percentage points (pp). On a Next 12 months row, it is Moatsight's estimate against the last 12 months.
- Yearly, 3 years: the yearly rate over the last 3 years, compounded. For a margin, its average change a year in percentage points.
- 8 quarters: the last 12 months at each of the latest 8 quarter ends, oldest on the left; the dot is the latest. The quarters themselves are on Financials.
- n/m: not meaningful, such as a rate of change from a loss.
- Color: a 1-year change in the gain color is better for the company, one in the loss color worse. The caret and the sign show which way it moved, and a row where lower is better says so in its details. Color judges the company's reported results, never its share price or Moatsight's estimates, and no other column is colored.
Price
No closing prices are stored for this listing yet.
Facts
- Exchange
- New York Stock Exchange · USD
- Kind
- Common stock
- Security
- Common Stock